Skip to main content
Log in

Bacteremic pneumococcal pneumonia associated with macrolide failure

  • Concise Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Despite rising rates of macrolide resistance to Streptococcus pneumoniae, the current guidelines for outpatient treatment of community-acquired pneumonia include a macrolide as initial empiric therapy. There have only been a few previously documented cases of macrolide treatment failure in community-acquired pneumonia and there is controversy as to whether macrolide resistance in S. pneumoniae is clinically important. Reported here are two cases of community-acquired pneumonia caused by S. pneumoniae, one of which was fatal, that failed to respond to clarithromycin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Jacobs MR (2002) In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 35:565–569

    Article  PubMed  Google Scholar 

  2. Rothermel CD (2004) Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes? Clin Infect Dis 38(Suppl 4):346–349

    Article  Google Scholar 

  3. Lonks JR (2004) What is the clinical impact of macrolide resistance? Current Infect Dis Reports 6:7–12

    Article  Google Scholar 

  4. Nuermberger E, Bishai WR (2004) The clinical significance of macrolide-resistant Streptococcus pneumoniae: it’s all relative. Clin Infect Dis 38:99–103

    Article  PubMed  Google Scholar 

  5. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH (2000) Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Infectious Community-Acquired Pneumonia Working Group. Clin Infect Dis 31:383–421

    Article  PubMed  CAS  Google Scholar 

  6. Bartlett JC, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis 31:347–382

    Article  PubMed  CAS  Google Scholar 

  7. Mandell LA, Bartlett JC, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433

    Article  PubMed  Google Scholar 

  8. File TM, Garau J, Blasi F et al (2004) Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125:1888–1901

    Article  PubMed  Google Scholar 

  9. Rzeseszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG (2004) A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 24:95–104

    Article  Google Scholar 

  10. Lonks JR, Garau J, Gomez L et al (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564

    Article  PubMed  CAS  Google Scholar 

  11. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J (2003) Breakthrough pneumococcal bacteremia in patients with clarithromycin or oral beta-lactams. J Antimicrob Chemother 51:691–696

    Article  PubMed  Google Scholar 

  12. National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Approved standard M100 S14. NCCLS, Wayne, PA

    Google Scholar 

  13. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L (1996) Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 40:2562–2566

    PubMed  CAS  Google Scholar 

  14. Farrell DJ, Jenkins SJ, Brown SD, Patel M, Lavin BS, Klugman KP (2005) Emergence and spread of Streptococcus pneumoniae with erm (B) and mef (A) resistance. Emerg Infect Dis 11:851–858

    PubMed  CAS  Google Scholar 

  15. Powis J, McGeer A, Green K et al (2004) In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 48:3305–3311

    Article  PubMed  CAS  Google Scholar 

  16. Hoban DJ, Wierzbowski AK, Nichol K et al (1998) Macrolide-resistant Streptococcus pneumoniae in Canada during 1998–1999: prevalence of mef (A) and erm (B) and susceptibilities to ketolides. Antimicrob Agents Chemother 45:147–150

    Google Scholar 

Download references

Acknowledgements

The authors wish to thank Dr. M. Gerson for reviewing the manuscript. J.D. has been a paid consultant and speaker for Sanofi–Aventis, Bristol–Myers Squibb and Pfizer. R.D. has been a paid consultant and speaker for Sanofi–Aventis, Bristol–Myers Squibb, Abbott Laboratories, Bayer and Roche.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Dylewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dylewski, J., Davidson, R. Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis 25, 39–42 (2006). https://doi.org/10.1007/s10096-005-0081-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-005-0081-z

Keywords

Navigation